U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefprozil – Oral products
  1. Development Resources

Cefprozil – Oral products

Exceptions to the recognized standard of CLSI M100

  Minimum Inhibitory
Concentrations
(mcg/mL)
Disk Diffusion
(zone diameter in mm)
Pathogen S I R S I R
Streptococcus pneumoniae ≤0.5 - ≥1 - - -

S = Susceptible; I = Intermediate; R = Resistant
Susceptibility interpretive criteria for microorganisms are based on a dosing regimen of 500 mg q12h (adults) or 15 mg/kg q12h (pediatrics)

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Haemophilus influenzae and parainfluenzae

Enterobacterales

Back to Top